Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274494 | 1.00 | CLK2 (0.43) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL24007658 | 0.85 | CLK2 (0.43) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL30274584 | 0.85 | CLK2 (0.43) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL30274556 | 0.78 | LRRK2 (0.44) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL13097046 | 0.78 | LRRK2 (0.44) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL29447089 | 0.76 | CLK2 (0.46) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL23753887 | 0.76 | MTOR (0.43) | CLK2LRRK2MKNK1AURKAAURKB | |
| SCHEMBL29978806 | 0.74 | IRAK1 (0.56) | IRAK1IRAK4 | |
| SCHEMBL9356119 | 0.74 | TRPV3 (0.33) | — | |
| SCHEMBL24920777 | 0.74 | ACVR2A (0.46) | CLK2LRRK2MKNK1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4146641-B1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | LILLY CO ELI (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-115768520-B | Substituted { 5-methoxy-6- [ (5-methoxypyridin-2-yl) methoxy ] pyridin-3-yl } methyl compounds as CSF-1R inhibitors | 伊莱利利公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| CN-115768520-A | Substituted { 5-methoxy-6- [ (5-methoxypyridin-2-yl) methoxy ] pyridin-3-yl } methyl compounds as CSF-1R inhibitors | 伊莱利利公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021225798-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | CSF1R, CSF3R, AGER | CLK2 2026/4885LRRK2 392/4885MKNK1 1550/4885 |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | CSF1R, CSF3R, IL1RN | CLK2 2480/4885LRRK2 637/4885MKNK1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.